

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 307/80, 405/12, A61K 31/44, 31/34, C07D 307/79, 405/14		A1	(11) International Publication Number: WO 97/20833
			(43) International Publication Date: 12 June 1997 (12.06.97)
(21) International Application Number: PCT/GB96/03012		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 5 December 1996 (05.12.96)		Published <i>With international search report.</i>	
(30) Priority Data: 9524832.4 5 December 1995 (05.12.95) GB 9610515.0 20 May 1996 (20.05.96) GB 9610712.3 22 May 1996 (22.05.96) GB			
(71) Applicant: CHIROSCIENCE LIMITED [GB/GB]; Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).			
(72) Inventors: DYKE, Hazel, Joan; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). KENDALL, Hannah, Jayne; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). LOWE, Christopher; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). MONTANA, John, Gary; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB).			
(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).			
(54) Title: BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES			
(57) Abstract Benzofuran carboxides and sulphonamides have therapeutic utility, e.g. in the treatment of inflammation and asthma, by virtue of their ability to inhibit phosphodiesterases and tumour necrosis factor.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES

Field of the Invention

The present invention relates to novel benzofuran carboxamides and sulphonamides, and to their formulation and use as pharmaceuticals.

5 Background of the Invention

EP-A-0187387 discloses benzofuransulphonamides having aldose reductase, platelet aggregation and arachidonic acid metabolism inhibitory activity.

US-A-4910193 discloses benzofuransulphonamides, in which the sulphonamide nitrogen is substituted by a variety of bridged saturated ring systems,
10 as medicaments suitable for the treatment of serotonin-induced gastrointestinal disturbances.

EP-A-0637586 discloses benzofuran derivatives, including 4-carboxamides, as acetylcholine esterase inhibitors.

WO-A-9408962 discloses benzofuran analogues as fibrinogen receptor
15 antagonists.

WO-A-9203427 discloses benzofuran-2-carboxamides, with a 3-substituent selected from hydroxy, acyloxy, alkoxy, optionally alkyl-substituted aminoalkoxy, alkylsulphonylamino, optionally alkyl-substituted aminoalkylsulphonyl or arylsulphonylamino, as a remedy for osteoporosis.

20 EP-A-0685475 discloses benzofuran-2-carboxamides as anti-inflammatory agents.

WO-A-9603399 discloses dihydrobenzofuran-4-carboxamides as inhibitors of phosphodiesterases.


Phosphodiesterases (PDE) and Tumour Necrosis Factor (TNF), their modes
25 of action and the therapeutic utilities of inhibitors thereof, are described in WO-A-9636595, WO-A-9636596 and WO-A-9636611, the contents of which are incorporated herein by reference. The same documents disclose sulphonamides having utility as PDE and TNF inhibitors.

Summary of the Invention

30 This invention is based on the discovery of novel compounds that can be used to treat disease states, for example disease states associated with proteins that mediate cellular activity, for example by inhibiting tumour necrosis factor and/or by

inhibiting phosphodiesterase IV. According to the invention, the novel compounds are of formula (i):

5



(i)

10 wherein Z is SO₂, CO or CS;

R₁ represents alkoxy optionally substituted with one or more halogens, OH or thioalkyl;

R₂ and R₃ are the same or different and are each H, R₆, COR₆, C(=NOR₁₁)R₆, CN, CO₂H, CO₂R₁₀, CONH₂, CONHR₆ or CON(R₆)₂;

15 R₄ represents H, arylalkyl, heteroarylalkyl, heterocycloalkyl, S(O)_mR₁₀ or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO₂R₇, SO₂NR₁₁R₁₂, CONR₁₁R₁₂, CN, carbonyl oxygen, NR₈R₉, COR₁₀ and S(O)_nR₁₀;

20 R₅ represents aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

in R₄ and/or R₅, the aryl/heteroaryl/heterocyclo portion is optionally substituted with one or more substituents alkyl-R₁₃ or R₁₃;

R₆ represents R₁₀ optionally substituted at any position with (one or more) R₁₄;

25 R₇ represents H, alkyl, arylalkyl, heterarylalkyl or heterocycloalkyl;

R₈ represents H, aryl, heteroaryl, heterocyclo, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxy carbonyl, arylsulphonyl, heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;

30 R₁₀ represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₉, R₁₁ and R₁₂ are the same or different, and are each H or R₁₀;

R_{13} represents alkyl or alkoxy optionally substituted by halogen, aryl, heteroaryl, heterocyclo, hydroxy, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO_2R_7 , $CONR_{11}R_{12}$, $SO_2NR_{11}R_{12}$, halogen, $-CN$, $-NR_8R_9$, COR_{10} , $S(O)_nR_{10}$, or carbonyl oxygen;

5 R_{14} represents OH , OR_{10} , carbonyl oxygen, NR_8R_9 , CN , CO_2H , CO_2R_{10} , $CONR_{11}R_{12}$ or COR_{10} ;

m represents 1-2; and

n represents 0-2;

and pharmaceutically-acceptable salts.

10 Combinations of substituents and/or variables are only permissible if such combinations result in stable compounds.

Description of the Invention

Suitable pharmaceutically-acceptable salts are pharmaceutically-acceptable base salts and pharmaceutically-acceptable acid addition salts. Certain of the
15 compounds of formula (i) which contain an acidic group form base salts. Suitable pharmaceutically-acceptable base salts include metal salts, such as alkali metal salts for example sodium salts, or organic amine salts such as that provided with ethylenediamine.

Certain of the compounds of formula (i) which contain an amino group form
20 acid addition salts. Suitable acid addition salts include pharmaceutically-acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically-acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphate, α -ketoglutarate, α -glycerophosphate and glucose-1-phosphate. The pharmaceutically-
25 acceptable salts of the compounds of formula (i) are prepared using conventional procedures.

It will be appreciated by those skilled in the art that some of the compounds of formula (i) may exist in more than one tautomeric form. This invention extends to all tautomeric forms.

30 It will be appreciated that the compounds according to the invention can contain one or more asymmetrically substituted atoms. The presence of one or more of these asymmetric centers in a compound of formula (i) can give rise to

stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers, and diastereoisomers and mixtures including racemic mixtures thereof.

When used herein the term alkyl whether used alone or when used as a part
5 of another group includes straight and branched chain alkyl groups containing up to 6 atoms. Alkoxy means an alkyl-O- group in which the alkyl group is as previously described. Aryloxy means an aryl-O- group in which the aryl group is as defined below. Heteroaryloxy means a heteroaryl-O- group and heterocyclooxy means a heterocyclo-O- group in which the heteroaryl and heterocyclo group are as defined
10 below. Arylalkyloxy means an aryl-alkyl-O- group. Heteroarylalkyloxy means a heteroaryl-alkyl-O group and heterocycloalkyloxy means a heterocyclo-alkyl-O-group. Aryloxyalkyl means an aryl-O-alkyl group, heteroaryloxyalkyl means a heteroaryl-O-alkyl group and heterocyclooxyalkyl means a heterocyclo-O-alkyl group. Alkylamino means an alkyl-N- group in which the alkyl group is as
15 previously defined, arylamino means aryl-N- and heteroarylamino means an heteroaryl-N- group (aryl and heteroaryl defined below). Thioalkyl means an alkyl-S-group. Cycloalkyl includes a non-aromatic cyclic or multicyclic ring system of about 3 to 10 carbon atoms. The cyclic alkyl may optionally be partially unsaturated. Aryl indicates carbocyclic radicals containing about 6 to 10 carbon
20 atoms. Arylalkyl means an aryl-alkyl- group wherein the aryl and alkyl are as described herein. Heteroarylalkyl means a heteroaryl-alkyl group and heterocycloalkyl means a heterocyclo-alkyl group. Alkylcarbonyl means an alkyl-CO-group in which the alkyl group is as previously described. Arylcarbonyl means an aryl-CO- group in which the aryl group is as previously described.
25 Heteroarylcarbonyl means a heteroaryl-CO- group and heterocyclocarbonyl means a heterocyclo-CO- group. Arylsulphonyl means an aryl-SO₂- group in which the aryl group is as previously described. Heteroarylsulphonyl means a heteroaryl-SO₂- group and heterocyclosulphonyl means a heterocyclo-SO₂- group. Alkoxycarbonyl means an alkyloxy-CO- group in which the alkoxy group is as previously described.
30 Alkylsulphonyl means an alkyl-SO₂- group in which the alkyl group is as previously described. Carbonyl oxygen means a -CO- group. It will be appreciated that a carbonyl oxygen can not be a substituent on an aryl or heteroaryl ring. Carbocyclic

ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system which may saturated or partially unsaturated. Heterocyclic ring means about a 5 to about a 10 membered monocyclic or multicyclic ring system (which may saturated or partially unsaturated) wherein one or more of the atoms in the ring system is an element other than carbon chosen from amongst nitrogen, oxygen or sulphur atoms. Heteroaryl means about a 5 to about a 10 membered aromatic monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur. Heterocyclo means about a 5 to about a 10 membered saturated or partially saturated monocyclic or multicyclic hydrocarbon ring system in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur. Halogen means fluorine, chlorine, bromine or iodine.

Compounds of the invention are useful for the treatment of TNF mediated disease states. "TNF mediated disease or disease states" means any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance, is a major component, and whose production or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF- β (also known as lymphotoxin) has close structural homology with TNF- α (also known as cachectin), and since each induces similar biologic responses and binds to the same cellular receptor, both TNF- α and TNF- β are inhibited by compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically indicated otherwise.

This invention relates to a method for mediating or inhibiting the enzymatic activity or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

PDE IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases, including: asthma, chronic bronchitis, atopic dermatitis,

atopic eczema, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, Bechet's disease, erythematosis, anaphylactoid purpura nephritis, joint inflammation, arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis and osteoarthritis, septic shock, sepsis, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and conditions associated with cerebral metabolic inhibition, such as cerebral senility, senile dementia (Alzheimer's disease), memory impairment associated with Parkinson's disease, depression and multi-infarct dementia. PDE IV inhibitors are also useful in conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke and intermittent claudication. Additionally, PDE IV inhibitors could have utility as gastroprotectants. A special embodiment of the therapeutic methods of the present invention is the treatment of asthma.

The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (i). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, *Herpes zoster* and *Herpes simplex*.

This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

The compounds of this invention may also be used in association with the veterinary treatment of animals, other than humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FIV) or other retroviral infection such as equine infectious anaemia virus, caprine arthritis virus, visna virus, maedi virus and other lentiviruses.

The compounds of this invention are also useful in treating parasite, yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production *in vivo*. A preferred disease state for treatment is fungal meningitis.


5 Compounds of the invention may also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.

10 The compounds of formula (i) are preferably in pharmaceutically-acceptable form. By pharmaceutically-acceptable form is meant, *inter alia*, of a pharmaceutically-acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. A pharmaceutically-acceptable level of purity will generally be at least 50% excluding normal pharmaceutical additives, preferably 75%, more
15 preferably 90% and still more preferably 95%.

20 The invention further provides a process for the preparation of a compound of formula (i), in which R_1 etc, m and n are as defined above. It will be appreciated that functional groups such as amino, hydroxyl or carboxyl groups present in the various compounds described below, and which it is desired to retain, may need to
25 be in protected forms before any reaction is initiated. In such instances, removal of the protecting group may be the final step in a particular reaction. Suitable protecting groups for such functionality will be apparent to those skilled in the art. For specific details, see Protective Groups in Organic Synthesis, Wiley Interscience, TW Greene. Thus the process for preparing compounds of formula (i) in which R_4
30 contains an -OH comprises of deprotecting (for example by hydrogenolysis or hydrolysis) a compound of formula (i) in which R_4 contains an appropriate -OP wherein P represents a suitable protecting group (e.g. benzyl).

 It will be appreciated that where a particular stereoisomer of formula (i) is required, this may be obtained by conventional resolution techniques such as high
30 performance liquid chromatography or the synthetic processes herein described may be performed using the appropriate homochiral starting material.

A process for the preparation of a compound of formula (i) wherein Z is SO₂ comprises reaction of an appropriate sulphonyl chloride of formula (ii) with a suitable amine of formula (iii)




wherein R_{1a} represents R₁ as defined in relation to formula (i) or a group convertible to R₁ and R_{2a}-R_{5a} similarly represent R₂-R₅ or groups convertible to R₂-R₅ respectively; and thereafter, if required, converting any group R_{1a} to R₁ and/or R_{2a} to R₂ and/or R_{3a} to R₃ and/or R_{4a} to R₄ and/or R_{5a} to R₅. The reaction of a sulphonyl chloride of formula (ii) with an amine of formula (iii) may be carried out under any suitable conditions known to those skilled in the art. Favourably, the reaction is carried out in the presence of a suitable base, for example an amine such as triethylamine, preferably in an appropriate solvent such as dichloromethane. In some cases a stronger base, such as sodium hydride, and a polar solvent such as dimethylformamide, will be required.


Sulphonyl chlorides of formula (ii) and amines (iii) are either commercially available, previously described compounds or are prepared using standard procedures known to those skilled in the art. Some of the amines of formula (iii) are conveniently prepared by reductive amination of an appropriate carbonyl compound with a suitable amine. This amination may be carried out under any suitable standard conditions known to those skilled in the art.

For example, a sulphonyl chloride of formula (ii) is conveniently prepared from the appropriate sulphonic acid (iv) by treatment with a suitable agent such as thionyl chloride or oxalyl chloride. Alternatively, a sulphonyl chloride of formula

(ii) may be prepared by sulphonylation of an appropriate benzofuran of formula (v) with a suitable sulphonylating agent such as chlorosulphonic acid.



Benzofurans of formula (v) may be prepared by any standard procedure known to those skilled in the art, for example by the reaction between an appropriate 2-hydroxybenzaldehyde or 2-hydroxyphenyl ketone (vi) and a suitable alkylating agent (vii) in the presence of an appropriate base (such as potassium carbonate or sodium hydroxide) in a suitable solvent (such as dimethylformamide or ethanol) at an appropriate temperature (for example reflux temperature of the solvent).




Examples of suitable alkylating agents include chloroacetone and chloroacetonitrile. Compounds (vi) and suitable alkylating agents (vii) are

commercially available, previously described compounds or may be prepared by standard procedures known to those skilled in the art.

A compound of formula (ia) may also be prepared by reaction of a sulphonyl chloride of formula (ii) with an amine of formula H_2NR_{5a} (viii) to provide a compound of formula (ia) in which R_{4a} is H, followed by reaction with an appropriate agent of formula $R_{4a}Y$ (ix) in which Y is a suitable leaving group such as a halogen. The reaction of a sulphonyl chloride of formula (ii) with an amine of formula (viii) may be carried out under any suitable conditions known to those skilled in the art. Favourably, the reaction is carried out in the presence of a suitable base, for example an amine such as triethylamine, preferably in an appropriate solvent such as dichloromethane. In some cases a stronger base such as sodium hydride, and a polar solvent such as dimethylformamide, may be required.


Amines of formula (viii) and agents (ix) are either commercially available, previously described compounds or are prepared using standard procedures known to those skilled in the art. The reaction of a compound of formula (ia) in which R_{4a} is H with an agent of formula (ix) may be carried out under any suitable conditions known to those skilled in the art. Favourably, the reaction is carried out using an appropriate base, such as sodium hydride, preferably in an appropriate solvent such as dimethylformamide. Agent (ix) can be an alkylating agent such as propyl bromide, an acylating agent such as benzoyl chloride or a sulphonylating agent such as methanesulphonyl chloride.

A process for the preparation of a compound of formula (i) wherein Z is CO comprises reaction of an appropriate carboxylic acid of formula (x) with a suitable amine of formula (iii)



wherein R_{1a} etc are as defined above; and thereafter, if required, converting any group R_{1a} to R_1 and/or R_{2a} to R_2 and/or R_{3a} to R_3 and/or R_{4a} to R_4 and/or R_{5a} to R_5 . The reaction of a carboxylic acid of formula (x) with an amine of formula (iii) may be carried out under any suitable conditions known to those skilled in the art, preferably those described above for (ii)→(ia). Favourably, the carboxylic acid is converted into an acid chloride, mixed anhydride or other activated intermediate prior to reaction with an amine of formula (iii).

Carboxylic acids of formula (x) are either commercially available, previously described compounds or are prepared using standard procedures known to those skilled in the art. For example, a carboxylic acid of formula (x) is conveniently prepared from an appropriate benzofuran of formula (v), using standard procedures known to those skilled in the art. For example, a benzofuran of formula (v) can be formylated to provide an aldehyde of formula (xi), which can then be oxidised to provide the corresponding acid of formula (x). Alternatively, a benzofuran of formula (v) can be brominated to provide a bromide of formula (vi), which can then be converted into a carboxylic acid of formula (x), for example by organometal-catalysed carboxylation.



A compound of formula (ib) may also be prepared by reaction of a carboxylic acid of formula (x) with an amine (viii) to provide a compound of formula (ib) in which R_4 is H, followed by reaction with an agent (ix). These reactions, with amine (viii) and agent (ix), can be carried out as described above. Preferably, the carboxylic acid is converted into an acid chloride, mixed anhydride or other activated intermediate prior to reaction with the amine (viii).

Compounds of formula (i) may also be prepared by interconversion of other compounds of formula (i). For example, a compound in which R_4 contains an alkoxy group may be prepared by appropriate alkylation of a compound in which R_4 contains a hydroxy group.

By way of further example, compounds in which R_2 and/or R_3 contain an oxime may be prepared from compounds in which R_2 and/or R_3 contain a carbonyl group. This transformation may be carried out using any appropriate standard conditions known to those skilled in the art. Compounds of formula (i) in which R_2 and/or R_3 contain a carbonyl group may be reduced using standard conditions known to those skilled in the art (for example with sodium borohydride in an appropriate solvent) to provide compounds in which R_2 and/or R_3 contains an alcohol group. Compounds in which R_2 and/or R_3 is alkyl may be prepared by reduction of compounds in which R_2 and/or R_3 is CO-alkyl using standard conditions known to those skilled in the art (for example hydrazine hydrate in the presence of a suitable base in an appropriate solvent). Other transformations may be carried out on compounds of formula (i) in which R_2 and/or R_3 contains a carbonyl group. Such transformations include, but are not limited to, reductive amination and alkylation. Any of the above transformations may be carried out either at the end of the synthesis or on an appropriate intermediate. Compounds of formula (i) in which Z is CS may be prepared from compounds of formula (i) in which Z is CO using any appropriate conditions known to those skilled in the art, for example by using Lawesson's reagent.

A compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may be administered *per se* or, preferably, as a pharmaceutical composition also comprising a pharmaceutically-acceptable carrier.

Accordingly, the present invention provides a pharmaceutical composition comprising a compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, and a pharmaceutically-acceptable carrier.

5 The active compound may be formulated for administration by any suitable route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral administration or through the respiratory
10 tract. Preparations may be designed to give slow release of the active ingredient.

The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc, the compounds of the invention are effective in the treatment of
15 humans.

The compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.

20 In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.

Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers
25 for example microcrystalline cellulose, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically-acceptable wetting agents such as sodium lauryl sulphate.

30 The solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used

to distribute the active agent throughout those compositions employing large quantities of fillers.

Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

Compositions may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebuliser, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 μm , such as from 0.1 to 50 μm , preferably less than 10 μm , for example from 1 to 10 μm , 1 to 5 μm or from 2 to 5 μm . Where appropriate, small amounts of other anti-asthmatics and bronchodilators for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, adjuvants such as local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, 5 except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

10 The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.

Compounds of formula (i), or if appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may also be 15 administered as a topical formulation in combination with conventional topical excipients.

Topical formulations may be presented as, for instance, ointments, creams or lotions, impregnated dressings, gels, gel sticks, spray and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist 20 drug penetration and emollients in ointments and creams. The formulations may contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.

Suitable cream, lotion, gel, stick, ointment, spray or aerosol formulations that may be used for compounds of formula (i) or if appropriate a pharmaceutically- 25 acceptable salt thereof, are conventional formulations well known in the art, for example, as described in standard text books such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, and the British and US Pharmacopoeias.

Suitably, the compound of formula (i), or if appropriate a pharmaceutically- 30 acceptable salt thereof, will comprise from about 0.5 to 20% by weight of the formulation, favourably from about 1 to 10%, for example 2 to 5%.

The dose of the compound used in the treatment of the invention will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and the relative efficacy of the compound. However, as a general guide suitable unit doses may be 0.1 to 1000mg, such as 0.5 to 200, 0.5 to 100 or 0.5 to 10mg, for example 0.5, 1, 2, 3, 4 or 5mg; and such unit doses may be administered more than once a day, for example 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total daily dosage for a 70kg adult is in the range of about 0.1 to 1000mg, that is in the range of about 0.001 to 20 mg/kg/day, such as 0.007 to 3, 0.007 to 1.4, 0.007 to 0.14 or 0.01 to 0.5mg/kg/day, for example 0.01, 0.02, 0.04, 0.05, 0.06, 0.08, 0.1 or 0.2 mg/kg/day, and such therapy may extend for a number of weeks or months.

When used herein the term "pharmaceutically-acceptable" encompasses materials suitable for both human and veterinary use.

The following Examples illustrate the invention.

Intermediate 1 N-Furfurylpropylamine

A solution of furfurylamine (1.0g) in dry DMF (3ml) was added to a cooled (0-5°C) stirred suspension of sodium hydride (60% dispersion; 0.46g) in DMF (5ml). After 15 minutes, a solution of 1-bromopropane (1.3g) in dry DMF (2ml) was added over 5 minutes. Stirring was continued for 1h and the reaction mixture was then allowed to warm to room temperature and stirred overnight. The reaction was quenched by the addition of dilute hydrochloric acid. Aqueous sodium hydrogen carbonate solution (100ml) was then added and the mixture was extracted with ethyl acetate (3 x 50ml). The combined organic extracts were washed with water, brine and then dried (magnesium sulphate) and evaporated *in vacuo*. The residue was distilled under reduced pressure to furnish the title compound (0.21g) as a colourless liquid.

Bp 85-90°C/15mmHg

Intermediate 2 2-Acetyl-4-bromo-7-methoxybenzofuran

A solution of bromine (5.5ml) in methanol (100ml) was added dropwise to a suspension of 2-acetyl-7-methoxybenzofuran (20g) in methanol (300ml) at 0°C. The ice bath was removed immediately and the mixture allowed to warm to room temperature. After 1 hour conversion was incomplete, so further bromine (0.75ml)

in methanol (25ml) was added and the mixture stirred overnight. The reaction was quenched using aqueous sodium metabisulphite solution (300ml) producing a precipitate that was filtered off and dried *in vacuo* to afford a brown solid (17.4g). TLC R_f 0.90 (ethyl acetate)

5 Intermediate 3 2-Acetyl-7-methoxybenzofuran-4-carboxylic acid

A mixture of Intermediate 2 (5g), triphenylphosphine (98mg), bis(triphenylphosphine)palladium (II) chloride (261mg), triethylamine (2.85ml) and water (1ml) in tetrahydrofuran (25ml) was purged with carbon monoxide gas in a Parr pressure reactor at 110 psi (758 kPa). This was heated to 110°C (pressure now 220
10 psi = 1517 kPa) and left for a week. On cooling and release of pressure the mixture was dissolved in 50% dichloromethane-water (200ml) and taken to pH12 using aqueous sodium hydroxide(1M). The separated aqueous phase was acidified to pH1 using dilute hydrochloric acid(1M) and the resultant slurry extracted with dichloromethane (3x100ml) then ethyl acetate (100ml). These combined organic
15 extracts were dried over magnesium sulphate, filtered and evaporated *in vacuo* to afford a yellow solid (2.58g).

TLC R_f 0.61 (ethyl acetate)

Intermediate 4 2-Acetyl-7-methoxybenzofuran-4-carbonyl chloride

Intermediate 3 (0.12g) was suspended in anhydrous dichloromethane (4ml)
20 at room temperature under nitrogen and oxalyl chloride (0.1ml) added followed by 3 drops of *N,N*-dimethylformamide. Evaporation *in vacuo* after 2 hours afforded the title compound as a yellow solid (-0.5g).

TLC R_f 0.60 (50%ethyl acetate in hexane)

Intermediate 5 2-Ethyl-7-methoxybenzofuran-4-carboxylic acid

25 2-Methyl-2-butene (9g) was added to a solution of 2-ethyl-7-methoxybenzofurancarboxaldehyde (5g) in 2-methyl-2-propanol (125ml). A solution of sodium dihydrogen phosphate monohydrate (20.7g) in water (15ml) was added, followed by sodium chlorite (11.05g). The resultant heterogeneous mixture was stirred vigorously for 30 minutes and then diluted with water (125ml). The mixture
30 was adjusted to pH 4 by the addition of 2M hydrochloric acid. The mixture was extracted with ethyl acetate (3x200ml) and the combined organic extracts were washed with water (2x200ml). The organic solution was concentrated to about 100ml

and then cooled to 10°C. The resultant precipitate was collected by filtration and dried at 50°C *in vacuo* to afford a beige solid (4g).

mp 215- 216°C

Intermediate 6 4-Amino-3-chloropyridine

5 A solution of 4-aminopyridine (4.0g) in concentrated hydrochloric acid (50ml) was treated at 80-85°C with an aqueous solution of hydrogen peroxide (13.5% w/v). The solution was cooled to 0°C. After 30 minutes, the solution was carefully treated with an aqueous sodium hydroxide solution (50%w/v) maintaining the temperature below 15°C. The white solid produced was obtained by filtration and air dried to
10 afford a white solid (4.9g).

R_f 0.36 (ethyl acetate).

mp 65-67°C.

Intermediate 7 4-(Propylamino)pyridine

15 4-Aminopyridine (0.499g) and propionaldehyde (0.5g) in dichloromethane (50ml) under an inert atmosphere were stirred at ambient temperature for 1.5 hours. Sodium triacetoxyborohydride (2.7g) was added and left overnight. The reaction mixture was washed with aqueous sodium bicarbonate (2x40ml) and extracted into dilute hydrochloric acid (2x40ml). These acidic extracts were basified using potassium hydroxide pellets and extracted into dichloromethane (2x80ml). The
20 combined organic extracts were dried over anhydrous magnesium sulphate, filtered and evaporated *in vacuo* to yield an oily residue (0.11g).

TLC R_f 0.49 (10% methanol in ethyl acetate).

Intermediate 8 2-Ethyl-7-methoxy-4-N-(3-carboethoxyphenyl)benzofuran-carboxamide

25 2-Ethyl-7-methoxybenzofuran-4-carbonyl chloride (1.0g) was added to a solution of ethyl 3-aminobenzoate (0.72g) in dichloromethane (30ml) at room temperature under an inert atmosphere and the reaction mixture stirred at room temperature overnight. The mixture was poured into dilute aqueous hydrochloric acid and extracted with ethyl acetate (2 x 50ml). The combined organic extracts
30 were washed with water (50ml), brine (50ml), dried (magnesium sulphate) and evaporated *in vacuo* to yield the title compound (1.39g) as a white solid.

mp 159-161°C.

The following compound was prepared according to the above procedure.

Intermediate 9 2-Ethyl-7-methoxy-4-*N*-(4-carboethoxyphenyl)benzofuran-carboxamide

Prepared from 2-ethyl-7-methoxybenzofuran-4-carbonyl chloride (1.3g) and ethyl 4-aminobenzoate (1.0g) to yield the title compound (0.76g) as a white solid.
TLC R_f 0.18 (25% ethyl acetate in hexane)

Intermediate 10 2-[1-(2,2-Dimethylpropyl)]-7-methoxybenzofuran

Sodium hydroxide (2.89g) was added to a solution of *o*-vanillin (10g) in ethanol (230ml) at 40°C. After 10 minutes, 1-bromopinacolone (9.7ml) was added and the resultant mixture was heated at 60°C for 4h then at reflux for a further 4h. The reaction mixture was cooled to room temperature and then concentrated *in vacuo*. The residue was partitioned between ethyl acetate (100ml) and 0.2% aqueous sodium hydroxide solution (100ml). The aqueous layer was extracted with ethyl acetate (2 x 75ml) and the combined organic extracts were washed with water (100ml) and brine (100ml). The solution was dried (magnesium sulphate) and concentrated *in vacuo* to furnish 2-[1-(2,2-dimethyl-1-oxopropyl)]-7-methoxybenzofuran as a brown oil.

Hydrazine hydrate (3.2ml) was added to a stirred suspension of 2-[1-(2,2-dimethyl-1-oxopropyl)]-7-methoxybenzofuran (3.0g) in ethylene glycol (38ml). The reaction mixture was heated to 65°C for 1h, then heated at reflux for 1.75h to afford a yellow solution. After cooling to room temperature, water (50ml) was added and the mixture extracted with dichloromethane (3 x 50ml). The combined organic extracts were washed with 2M aqueous hydrochloric acid (15ml), water (3 x 20ml) and brine 50ml). The solution was dried (magnesium sulphate) and concentrated *in vacuo*. Purification by column chromatography on silica, eluting with 5% ethyl acetate in hexane yielded the title compound (1.92g) as a colourless oil.
TLC R_f 0.35 (5% ethyl acetate in hexane)

Intermediate 11 2-[1-(2,2-Dimethylpropyl)]-7-methoxybenzofuran-4-carboxaldehyde

Phosphorus oxychloride (1.64ml) was added dropwise to DMF (1ml) at 0°C under nitrogen and stirred for 10 minutes. A solution of 2-[1-(2,2-dimethylpropyl)]-7-methoxybenzofuran (1.92g) in DMF (3.5ml) was then added. A pale yellow solid

formed and the reaction mixture was heated to 100°C for 2h. The reaction mixture was allowed to cool to room temperature overnight. A solution of 50% aqueous sodium acetate trihydrate (20ml) was added cautiously and the resultant mixture was extracted with MTBE (3 x 25ml). The combined organic phases were washed with water (2 x 20ml), saturated aqueous sodium hydrogen carbonate solution (20ml) and brine (30ml). The solution was dried (magnesium sulphate) and concentrated *in vacuo* to provide the title compound (2.14g) as a light brown oil.

TLC R_f 0.25 (5% ethyl acetate in hexane)

Intermediate 12 2-[1-(2,2-Dimethylpropyl)]-7-methoxybenzofuran-4-carboxylic acid

Prepared from Intermediate 11 (2.14g), by the same procedure as for Intermediate 5. The title compound (1.81g) was obtained as a pale yellow solid. mp 173-174°C

Example 1 2-Acetyl-7-methoxy-N-[3-pyridylmethyl]-4-benzofuransulphonamide

Triethylamine (0.43ml) was added to a solution of 2-acetyl-7-methoxy-4-benzofuransulphonyl chloride (600mg) and 3-(aminomethyl)pyridine (0.25ml) in dichloromethane at room temperature. The resultant mixture was stirred for 20 hours and then diluted with dichloromethane (20ml). The solution was washed with water (20ml) and brine (20ml) and dried (MgSO₄). Concentration *in vacuo* provided a dark oil which was applied to a silica column and eluted with 2% methanol in dichloromethane. The title compound was obtained as a pale yellow solid (161mg). Mp 168-170°C

Example 2 2-Acetyl-N-benzyl-7-methoxy-4-benzofuransulphonamide

Prepared from 2-acetyl-7-methoxy-4-benzofuransulphonyl chloride and benzylamine using the procedure of Example 1.

TLC R_f 0.25 (30% ethyl acetate in hexane)

Mp 158-159°C

Example 3 2-Acetyl-N-furfuryl-7-methoxy-4-benzofuransulphonamide

Prepared using the procedure of Example 1. Trituration with diethyl ether afforded the title compound (0.33g) as a white solid.

TLC R_f 0.42 (50% ethyl acetate in hexane)

Mp 182-184°C

Example 4 2-Acetyl-*N*-furfuryl-*N*-propyl-7-methoxy-4-benzofuransulphonamide

Prepared from 2-acetyl-7-methoxy-4-benzofuransulphonyl chloride and Intermediate 1 using the procedure of Example 1. Purification by column chromatography on silica eluting with 5% ethyl acetate in dichloromethane gave the title compound (100mg) as an off-white solid.

TLC R_f 0.6 (5% ethyl acetate in dichloromethane)

Mp 109-111°C

Example 5 *N*-Benzyl-2-ethyl-7-methoxy-4-benzofuransulphonamide

Hydrazine (6.96g) was added to a suspension of Example 2 (10g) in ethylene glycol (120ml) at 38°C. The mixture was heated and potassium carbonate (7.7g) was added at 65°C. Heating was continued until a temperature of 170°C was attained. The mixture was cooled to room temperature and poured into a mixture of brine (300ml), water (300ml) and ethyl acetate (300ml). The aqueous layer was extracted with ethyl acetate (2x300ml) and the combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. The residue was applied to a silica column and eluted with 30% ethyl acetate in heptane to provide the title compound as an off-white solid (5.1g).

TLC R_f 0.13 (30% ethyl acetate in hexane)

Mp 105-107°C

The following compound was prepared using the above procedure:

Example 6 2-Ethyl-7-methoxy-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide

Purification by column chromatography on silica eluting with 1% triethylamine/10% methanol in ethyl acetate yielded the title compound as a pale yellow solid (0.36g).

TLC R_f 0.51 (10% methanol in ethyl acetate)

Mp 115-117°C

Example 7 2-Acetyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide

A solution of Example 1 (126mg) in dry DMF (2ml) was cooled to 0°C under nitrogen. Sodium hydride (60% dispersion in oil; 17mg) was added and the mixture stirred for 15 minutes. Methanesulphonyl chloride (54 µl) was added and the resultant mixture was stirred at 0°C for 1 hour and then at room temperature for

16 hours. Water (1ml) was added and the mixture concentrated *in vacuo*. The residue was partitioned between water (10ml) and dichloromethane (15ml) and the layers separated. The aqueous phase was extracted with dichloromethane (2x15ml) and the combined organic extracts were washed with brine (15ml), dried (MgSO₄) and concentrated *in vacuo*. The residue was applied to a silica column and eluted with 2% methanol in dichloromethane. The titled compound was obtained as a pale yellow solid (48mg).

TLC R_f 0.15 (2% methanol in dichloromethane)

Mp 171-172°C

The following compounds were prepared using the above procedure.

Example 8 *N*-Benzyl-2-ethyl-*N*-(methanesulphonyl)-7-methoxy-4-benzofuran-sulphonamide

This was prepared from Example 5.

TLC R_f 0.75 (50% ethyl acetate in hexane)

IR (thin film) n_{\max} 1620, 1594, 1366, 1323, 1164, 1098 cm⁻¹

Example 9 *N*-Benzyl-2-ethyl-7-methoxy-*N*-(2-pyridylmethyl)-4-benzofuran-sulphonamide

This was prepared as above using 2-(chloromethyl)pyridine.

TLC R_f 0.38 (50% ethyl acetate in hexane)

IR (thin film) n_{\max} 1618, 1592, 1332, 1161, 1095 cm⁻¹

Example 10 2-Ethyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide

This was prepared from Example 6. Purification by column chromatography eluting with 10% methanol in ethyl acetate afforded the title compound as a white foam (87mg).

TLC R_f 0.65 (10% methanol in ethyl acetate)

IR (thin film) n_{\max} 1575, 1405, 1290, 1164 cm⁻¹

Example 11 2-Ethyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide hydrochloride

A solution of hydrogen chloride in ether (1M solution, 1.5ml) was added to a solution of Example 10 (0.1g) in dry dichloromethane (4ml) under nitrogen. The resultant solution was stirred at room temperature for 90 minutes. Ether (10ml) was

added and the resultant precipitate was collected by filtration to provide the title compound as a cream-coloured solid (0.09g).

Similarly prepared:

Example 12 2-Acetyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide hydrochloride

From Example 7 (0.08g) as a pale yellow solid (0.06g).

Example 13 2-Acetyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofuran-carboxamide

Sodium hydride (0.03g) was added to a solution of 4-amino-3,5-dichloropyridine (0.08g) in anhydrous *N,N*-dimethylformamide (1ml) at room temperature under nitrogen. This stirred mixture was warmed to 60°C for 1 hour before addition of Intermediate 4 washed in with anhydrous *N,N*-dimethylformamide (2ml). The brown mixture was heated at 60°C for 4 hours, allowed to cool, poured into water(100ml) and extracted into ethyl acetate (2x50ml). These organic extracts were washed with water (50ml) and saturated brine(50ml) then dried over magnesium sulphate, filtered and evaporated *in vacuo* to give a crude residue (0.17g). Purification by column chromatography on silica eluting with a 20-80% ethyl acetate in hexane gradient afforded a white solid (0.04g).

TLC R_f 0.20 (50% ethyl acetate in hexane)

mp 252-254°C

Example 14 2-Ethyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofuran-carboxamide

A suspension of Intermediate 5 (300mg) in dry toluene (50ml) under an inert atmosphere was treated with thionyl chloride (2ml) and heated to reflux for 2 hours. The cooled reaction mixture was evaporated *in vacuo* and the residue azeotroped with dry toluene (2x10ml) to afford the acid chloride as a white solid (325mg).

4-Amino-3,5-dichloropyridine(230mg) in dry *N,N*-dimethylformamide(20ml) under an inert atmosphere was treated with sodium bis(trimethylsilyl)amine (1.5ml; 1.0M in tetrahydrofuran) at ambient temperature for 30 minutes. The solid acid chloride (325mg) was added to this mixture and heated at 50°C for 3 hours then allowed to cool overnight. It was evaporated *in vacuo*, saturated aqueous sodium bicarbonate (50ml) added and extracted into dichloromethane (2x50ml). These

extracts were dried over magnesium sulphate, filtered and evaporated *in vacuo* to give a crude residue. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a white solid (210mg).

TLC R_f 0.15 (25% ethyl acetate in hexane)

5 mp 199-200°C

Example 15 2-Acetyl-7-methoxy-4-N-(pyrid-4-yl)benzofurancarboxamide

A solution of Intermediate 4 (164mg) in anhydrous dichloromethane (10ml) under nitrogen at 0°C, was treated with 4-aminopyridine (0.07g), triethylamine (0.12g) and 4-dimethylaminopyridine (2mg). This solution was allowed to warm to room temperature and stirred overnight. The reaction mixture was washed with saturated aqueous sodium bicarbonate (10ml), water (10ml) and saturated brine (10ml) then dried over magnesium sulphate, filtered and evaporated *in vacuo* to give a crude residue. Purification by column chromatography on silica eluting with 5% methanol in dichloromethane afforded a pale yellow solid (85mg).

15 TLC R_f 0.27 (5% methanol in dichloromethane)

mp 247-248°C (dec)

Example 16 2-Acetyl-7-methoxy-4-[N-(pyrid-4-yl)-N-propyl]benzofuran-carboxamide

Intermediate 7 (0.08g) was treated with Intermediate 4 (0.15g) as in Example 15 to afford a pale yellow foam (129mg).

TLC R_f 0.57 (5% methanol in dichloromethane)

IR (film) ; 1292, 1587, 1647, 1685 cm⁻¹

Example 17 2-Acetyl-7-methoxy-4-N-(2-chlorophenyl)benzofurancarboxamide

2-Chloroaniline (0.42ml) was treated with Intermediate 4 (1g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a solid (137mg).

mp 179 - 181°C

Example 18 2-Acetyl-7-methoxy-4-N-(2,6-dimethylphenyl)benzofurancarboxamide

2,6-Dimethylaniline (0.49ml) was treated with Intermediate 4 (1g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a solid (255mg).

TLC R_f 0.23 (50% ethyl acetate in hexane)

mp 225 - 226°C

Example 19 2-Acetyl-7-methoxy-4-N-(4-methoxyphenyl)benzofurancarboxamide

4-Methoxyaniline (567mg) was treated with Intermediate 4 (1.19g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in heptane afforded a yellow solid (103mg).

TLC R_f 0.26 (50% ethyl acetate in heptane)

Example 20 2-Acetyl-7-methoxy-4-N-(3-bromo-5-methylpyrid-2-yl)benzofurancarboxamide

2-Amino-3-bromo-5-methylpyridine (0.64g) in dry tetrahydrofuran (20ml) was treated with sodium hydride (0.15g; 60% dispersion in oil) under an inert atmosphere at ambient temperature for 15 minutes. A solution of Intermediate 4 (0.86g) in dry tetrahydrofuran (10ml) was added and then stirred overnight before evaporation *in vacuo*. Aqueous sodium bicarbonate (50ml) was added and the mixture extracted with ethyl acetate (2x50ml). These extracts were dried over magnesium sulphate, filtered and evaporated *in vacuo*. The crude residue was purified by column chromatography on silica eluting with 50% ethyl acetate in hexane to afford a pale yellow powder (95mg).

TLC R_f 0.5 (50% ethyl acetate in hexane)

Example 21 2-Acetyl-7-methoxy-4-N-(3-methylphenyl)benzofurancarboxamide

m-Toluidine (0.42ml) was treated with Intermediate 4 (1g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a yellow solid (200mg).

TLC R_f 0.5 (50% ethyl acetate in hexane)

mp 193 - 195°C

Example 22 2-Acetyl-7-methoxy-4-N-(3,5-dichloropyrid-2-yl)benzofurancarboxamide

2-Amino-3,5-dichloropyridine (0.758g) was treated with Intermediate 4 (1.17g) as in Example 13 using *N,N*-dimethylformamide as a cosolvent. Purification by column chromatography on silica eluting with 3% methanol in dichloromethane afforded a yellow solid (13mg).

TLC R_f 0.5 (50% ethyl acetate in hexane)

Example 23 2-Acetyl-7-methoxy-4-*N*-(2-methylphenyl)benzofurancarboxamide

2-Methylaniline (0.21ml) was treated with Intermediate 4 (0.5g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a yellow solid (128mg).

5 TLC R_f 0.24 (50% ethyl acetate in hexane)

mp 174 - 175°C

Example 24 2-Acetyl-7-methoxy-4-*N*-(4-methoxy-2-methylphenyl)benzofuran-carboxamide

10 4-Methoxy-2-methylaniline (0.56ml) was treated with Intermediate 4 (1.0g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a yellow solid (235mg).

TLC R_f 0.25 (50% ethyl acetate in hexane)

mp 217 - 218°C

Example 25 2-Acetyl-7-methoxy-4-*N*-(pyrimidin-4-yl)benzofurancarboxamide

15 4-Aminopyrimidine (0.376g) was treated with Intermediate 4 (1g) as in Example 15. Purification by column chromatography on silica eluting with a 0-10% methanol in ethyl acetate gradient afforded a yellow solid (0.14g).

TLC R_f 0.49 (10% methanol in ethyl acetate)

mp 212 - 214°C

20 **Example 26** 2-Acetyl-7-methoxy-4-*N*-(2-trifluoromethylphenyl)benzofuran-carboxamide

2-Aminobenzotrifluoride (0.5ml) was treated with Intermediate 4 (1.0g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a yellow solid (0.12g).

25 mp 164 - 166°C

Example 27 2-Acetyl-7-methoxy-4-*N*-[2-(piperidin-1-yl)phenyl]benzofuran-carboxamide

30 N-(2-Aminophenyl)piperidine (700mg) was treated with Intermediate 4 (1.0g) as in Example 15. Purification by column chromatography on silica eluting with 40% ethyl acetate in hexane afforded a yellow solid (300mg).

TLC R_f 0.5 (50% ethyl acetate in hexane)

mp 170 - 171°C

Example 28 2-Acetyl-7-methoxy-4-N-(3-chloropyrid-4-yl)benzofurancarboxamide

Intermediate 6 (0.26g) was treated with Intermediate 4 (0.5g) as in Example 13, except that the initial anion generation was performed at ambient temperature and using 15-crown-5 (0.90g). Purification by column chromatography on silica eluting with 5% methanol in dichloromethane afforded an off-white solid (0.08g).
TLC R_f 0.65 (5% methanol in dichloromethane)
mp 197 - 200°C

Example 29 2-Acetyl-7-methoxy-4-N-(2-trifluoromethoxyphenyl)benzofuran-carboxamide

2-Trifluoromethoxyaniline (0.49g) was treated with Intermediate 4 (0.7g) as in Example 15. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded a yellow solid (0.065g).
TLC R_f 0.49 (50% ethyl acetate in hexane)
mp 163 - 165°C

Example 30 2-Acetyl-7-methoxy-4-N-(2-ethylphenyl)benzofurancarboxamide

2-Ethylaniline (0.48g) was treated with Intermediate 4 (1.0g) as in Example 15. Purification by column chromatography on silica eluting with 25% ethyl acetate in hexane afforded an off-white solid (310mg).
TLC R_f 0.13 (25% ethyl acetate in hexane)
mp 174 - 175°C

Example 31 2-Acetyl-7-methoxy-4-N-(2-biphenyl)benzofurancarboxamide

2-Aminobiphenyl (0.5g) was treated with Intermediate 4 (0.73g) as in Example 15. Purification by column chromatography on silica eluting with 5% methanol in dichloromethane then trituration with diethyl ether afforded a cream solid (0.17g).
TLC R_f 0.5 (50% ethyl acetate in hexane)
mp 131 - 133°C

Example 32 2-Acetyl-7-methoxy-4-N-(3-methylpyrid-2-yl)benzofurancarboxamide

2-Amino-3-picoline (0.32ml) was treated with Intermediate 4 (0.73g) as in Example 15. Purification by column chromatography on silica eluting with 5% methanol in dichloromethane afforded a yellow solid (0.12g).
TLC R_f 0.40 (5% methanol in dichloromethane)

Example 33 2-Ethyl-7-methoxy-4-N-(2-chloropyrid-3-yl)benzofurancarboxamide

3-Amino-2-chloropyridine (0.88g) was treated with Intermediate 4 (1.8g) as in Example 13 except that the anion generation was performed at ambient temperature for 1.5 hours. Purification by flash chromatography on silica eluting
5 with hot ethyl acetate then trituration with diethyl ether afforded a beige solid (0.53g).

TLC R_f 0.35 (50% ethyl acetate in hexane)

mp 124 - 125°C

Example 34 2-Acetyl-7-methoxy-4-N-(2-methoxyphenyl)benzofuran-carboxamide

10 o-Anisidine (0.49g) was treated with Intermediate 4 (1g) as in Example 15. Purification by column chromatography on silica eluting with 30% ethyl acetate in hexane afforded a yellow solid (160mg).

Example 35 2-Acetyl-7-methoxy-4-N-(2-chloropyrid-3-yl)benzofurancarboxamide

3-Amino-2-chloropyridine (509mg) was treated with Intermediate 4 (1.0g) as
15 in Example 13. Purification by column chromatography on silica eluting with 25% ethyl acetate in hexane afforded a yellow solid (205mg).

Example 36 2-Acetyl-7-methoxy-4-N-(2-chloro-6-methylphenyl)benzofuran-carboxamide

2-Chloro-6-methylaniline (0.56g) was treated with Intermediate 4 (1g) as in
20 Example 15. Purification by recrystallisation from dichloromethane afforded a brown solid (160mg).

TLC R_f 0.4 (5% methanol in dichloromethane)

Example 37 2-(1-Hydroxyethyl)-7-methoxy-4-N-(3,5-dichloropyrid-4-yl)benzofurancarboxamide

25 Example 13 (0.50g) was suspended in dry methanol (20ml) and treated with sodium borohydride (196mg) at ambient temperature. Some external ice cooling was required then stirred overnight. The reaction mixture was poured into water and extracted into ethyl acetate. Evaporation *in vacuo* yielded a solid that was purified
30 by column chromatography using 5% methanol in dichloromethane to afford a white solid (400mg).

TLC R_f 0.52 (80% ethyl acetate in heptane)

mp 229 - 231°C

Example 38 2-(3-Pyrid-3-yl-1-oxopropyl)-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofurancarboxamide

A solution of Example 13 (0.40g) in dry *N,N*-dimethylformamide (5ml) under an inert atmosphere was cooled to -10°C and sodium hydride (60% dispersion in oil, 0.11g) was added over 30 minutes. After 1 hour at -10°C, 3-picolyl chloride hydrochloride (0.20g) was added and the mixture stirred for a further 2 hours before allowing to warm to room temperature overnight. It was poured into water and extracted into ethyl acetate. These extracts were washed with water and saturated brine then dried over anhydrous magnesium sulphate, filtered and evaporated *in vacuo*. The resultant residue was purified by column chromatography using a 3-10% methanol in dichloromethane gradient then triturated with diethyl ether to yield a beige powder (15.5mg).

TLC R_f 0.27 (10% methanol in dichloromethane).

Example 39 2-(1-Benzyl oxyimino)ethyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofurancarboxamide

Example 13 (100mg) was refluxed under Dean-Stark conditions in dry toluene (40ml) with dry pyridine (64 μ l) and O-benzylhydroxylamine hydrochloride (126mg) under an inert atmosphere. After 2 hours the mixture was allowed to cool and left stirring overnight. Addition of methanol and acetone formed a precipitate. This was filtered off to afford a solid (26mg).

TLC R_f 0.45 (50%ethyl acetate in hexane).

Example 40 2-Ethyl-7-methoxy-4-*N*-(3-carboxyphenyl)benzofurancarboxamide

A solution of Intermediate 8 (0.78g) in THF (25ml) was treated with a solution of lithium hydroxide monohydrate (0.18g) in water (25ml) and the reaction mixture stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo*, diluted with water (100ml) and acidified with dilute aqueous hydrochloric acid. The resulting white precipitate was collected, washed with water and dried *in vacuo* to afford the title compound (0.68g) as a white solid.

TLC R_f 0.35 (5% methanol in dichloromethane)

mp 265-267°C

The following compound was prepared according to the above procedure.

Example 41 2-Ethyl-7-methoxy-4-*N*-(4-carboxyphenyl)benzofurancarboxamide

Prepared from Intermediate 9 (0.67g) to afford the title compound (0.59g) as a white solid.

TLC R_f 0.4 (5% methanol in dichloromethane)

5 mp 279-280°C

Example 42 2-[1-(2,2-Dimethylpropyl)]-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofurancarboxamide

Thionyl chloride (1.65ml) was added to a suspension of Intermediate 12 (0.59g) in toluene (10ml) and the mixture heated at reflux for 3h. The mixture was stirred at room temperature overnight and concentrated *in vacuo*. The residue was azeotroped several times with toluene to furnish 2-[1-(2,2-dimethylpropyl)]-7-methoxybenzofuran-4-carbonyl chloride (0.63g).

Sodium hexamethyldisilazide (1M solution in THF, 4.5ml) was added to a solution of 4-amino-3,5-dichloroaminopyridine (0.74g) in dry DMF (2ml) at room temperature under nitrogen. The mixture was stirred at room temperature for 0.5h, then warmed to 50°C. A solution of 2-[1-(2,2-dimethylpropyl)]-7-methoxybenzofuran-4-carbonyl chloride (0.63g) in DMF was added and the reaction mixture stirred for a further 3h, then at room temperature for 16h. Water (20ml) was added and the resultant precipitate was collected and dried *in vacuo*. Purification by column chromatography on silica, eluting with 25% ethyl acetate in hexane afforded the title compound (0.29g) as a pale yellow solid.

TLC R_f 0.4 (50% ethyl acetate in hexane)

mp 164-165°C

Assay methods

25 The assays used to confirm the phosphodiesterase IV inhibitory activity of compounds of formula (i) are standard assay procedures as disclosed by Schilling *et al*, Anal. Biochem. 216:154 (1994), Thompson and Strada, Adv. Cycl. Nucl. Res. 8:119 (1979) and Gristwood and Owen, Br. J. Pharmacol. 87:91P (1986).

30 Compounds of formula (i) have exhibited activity at levels consistent with those believed to be useful in treating phosphodiesterase IV-related disease states in those assays.

The ability of compounds of formula (i) to inhibit TNF production in human monocytes is measured as follows. Peripheral blood mononuclear cells are prepared from freshly taken blood by standard procedures. Cells are plated out in RPMI1640 +1% foetal calf serum in the presence and absence of inhibitors. LPS (100 ng/ml) is added and cultures are incubated for 22 h at 37°C in an atmosphere of 95% air/5% CO₂. Supernatants are tested for TNF α by ELISA using commercially available kits.

In vivo activity in a skin eosinophilia model is determined by using the methods described by Hellewell *et al*, Br. J. Pharmacol. 111:811 (1994) and Br. J. Pharmacol. 110:416 (1993). Activity in a lung model is measured using the procedures described by Kallos and Kallos, Int. Archs. Allergy Appl. Immunol. 73:77 (1984), and Sanjar *et al*, Br. J. Pharmacol. 99:679 (1990).


An additional lung model, which allows measurement of inhibition of the early and late-phase asthmatic responses and also the inhibition of airway hyperreactivity, is described by Broadley *et al*, Pulmonary Pharmacol. 7:311 (1994), J. Immunological Methods 190:51 (1996) and British J. Pharmacol. 116:2351 (1995). Compounds of the invention show activity in this model.

CLAIMS

1. A compound of the general formula (i)

5

(i)



10

wherein Z is SO₂, CO or CS;

R₁ represents alkoxy optionally substituted with one or more halogens, OH or thioalkyl;

R₂ and R₃ are the same or different and are each H, R₆, COR₆, C(=NOR₁₁)R₆, CN, CO₂H, CO₂R₁₀, CONH₂, CONHR₆ or CON(R₆)₂;

15

R₄ represents H, arylalkyl, heteroarylalkyl, heterocycloalkyl, S(O)_mR₁₀ or alkyl optionally substituted with one or more substituents chosen from hydroxy, alkoxy, CO₂R₇, SO₂NR₁₁R₁₂, CONR₁₁R₁₂, CN, carbonyl oxygen, NR₈R₉, COR₁₀ and S(O)_nR₁₀;

20

R₅ represents aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

in R₄ and/or R₅ the aryl/heteroaryl/heterocyclo portion is optionally substituted with one or more substituents alkyl-R₁₃ or R₁₃;

R₆ represents R₁₀ optionally substituted at any position with R₁₄;

R₇ represents H, alkyl, arylalkyl, heteroarylalkyl or heterocycloalkyl;

25

R₈ represents H, aryl, heteroaryl, heterocyclo, alkyl, arylalkyl, heteroarylalkyl, heterocycloalkyl, alkylcarbonyl, alkoxy carbonyl, arylsulphonyl, heteroarylsulphonyl, heterocyclosulphonyl, arylcarbonyl, heteroarylcarbonyl, heterocyclocarbonyl or alkylsulphonyl;

30

R₁₀ represents alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl;

R₉, R₁₁ and R₁₂ are the same or different and are each H or R₁₀;

R_{13} represents alkyl or alkoxy optionally substituted by halogen, aryl, heteroaryl, heterocyclo, hydroxy, aryloxy, heteroaryloxy, heterocyclooxy, arylalkyloxy, heteroarylalkyloxy, heterocycloalkyloxy, CO_2R_7 , $CONR_{11}R_{12}$, $SO_2NR_{11}R_{12}$, halogen, $-CN$, $-NR_8R_9$, COR_{10} , $S(O)_mR_{10}$ or carbonyl oxygen;

5 R_{14} represents OH , carbonyl oxygen, OR_{10} , NR_8R_9 , CN , CO_2H , CO_2R_{10} , $CONR_{11}R_{12}$ or COR_{10} ;

m is an integer of up to 2; and

n represents 0-2;

or a pharmaceutically-acceptable salt thereof.

10 2. A compound of claim 1, wherein

Z is SO_2 ;

R_1 is C_{1-3} alkoxy optionally substituted by one or more halogens;

R_2 and R_3 are each independently selected from H , CN , CO_2H (or C_{1-6} alkyl esters thereof or C_{1-6} alkyl amides thereof), and alkyl optionally substituted with one or more substituents chosen from carbonyl oxygen, hydroxy, alkoxy, aryloxy, arylalkoxy, alkylamino, arylalkylamino or arylamino, and cycloalkyl optionally substituted with one or more substituents chosen from carbonyl oxygen, hydroxy, C_{1-6} alkoxy, aryloxy, arylalkyloxy, C_{1-6} alkylamino, arylalkylamino or arylamino;

15 R_4 represents H , arylalkyl, heteroarylalkyl, $S(O)_mR_{10}$, COR_{10} , alkyl optionally substituted with carbonyl oxygen, NR_8R_9 , $S(O)_nR_{10}$, COR_{10} , hydroxy, CO_2H (or C_{1-6} alkyl esters thereof or C_{1-6} alkyl amides thereof) or CN ;

R_5 represents arylalkyl or heteroarylalkyl;

R_8 represents H , alkyl, alkylcarbonyl, alkoxycarbonyl, arylsulphonyl, arylcarbonyl or alkylsulphonyl;

25 R_9 represents H or alkyl; and

R_{10} represents alkyl, arylalkyl or heteroarylalkyl;

3. A compound of claim 1, wherein

Z is SO_2 ;

R_2 and R_3 are each independently selected from H , R_6 and COR_6 ; and

30 R_6 is alkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl or heterocycloalkyl.

4. A compound of claim 1, wherein Z is CO, and R₂ and R₃ are as defined in claim 3.
5. A compound of claim 1, selected from
2-acetyl-*N*-benzyl-7-methoxy-4-benzofuransulphonamide,
5 *N*-benzyl-2-ethyl-7-methoxy-4-benzofuransulphonamide,
2-acetyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide,
N-benzyl-2-ethyl-*N*-(methanesulphonyl)-7-methoxy-4-benzofuransulphonamide,
and
10 *N*-benzyl-2-ethyl-7-methoxy-*N*-(2-pyridylmethyl)-4-benzofuransulphonamide.
6. A compound of claim 1, selected from
2-acetyl-*N*-furfuryl-7-methoxy-4-benzofuransulphonamide,
2-acetyl-*N*-furfuryl-*N*-propyl-7-methoxy-4-benzofuransulphonamide,
2-ethyl-7-methoxy-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide, and
15 2-ethyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide.
7. A compound of claim 1, selected from 2-acetyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofurancarboxamide and 2-acetyl-7-methoxy-4-*N*-(pyrid-4-yl)benzofuran-carboxamide.
- 20 8. A compound of claim 1, selected from 2-ethyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide hydrochloride and 2-acetyl-7-methoxy-*N*-(methanesulphonyl)-*N*-(3-pyridylmethyl)-4-benzofuransulphonamide hydrochloride.
9. A compound of claim 1, selected from
25 2-ethyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofurancarboxamide,
2-acetyl-7-methoxy-4-[*N*-(pyrid-4-yl)-*N*-propyl]benzofurancarboxamide,
2-acetyl-7-methoxy-4-*N*-(2-chlorophenyl)benzofurancarboxamide,
2-acetyl-7-methoxy-4-*N*-(2,6-dimethylphenyl)benzofurancarboxamide,
2-acetyl-7-methoxy-4-*N*-(4-methoxyphenyl)benzofurancarboxamide,
30 2-acetyl-7-methoxy-4-*N*-(3-bromo-5-methylpyrid-2-yl)benzofurancarboxamide,
2-acetyl-7-methoxy-4-*N*-(3-methylphenyl)benzofurancarboxamide,
2-acetyl-7-methoxy-4-*N*-(3,5-dichloropyrid-2-yl)benzofurancarboxamide,

- 2-acetyl-7-methoxy-4-*N*-(2-methylphenyl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(4-methoxy-2-methylphenyl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(pyrimidin-4-yl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-trifluoromethylphenyl)benzofurancarboxamide,
 5 2-acetyl-7-methoxy-4-*N*-[2-(piperidin-1-yl)phenyl]benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(3-chloropyrid-4-yl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-trifluoromethoxyphenyl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-ethylphenyl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-biphenyl)benzofurancarboxamide,
 10 2-acetyl-7-methoxy-4-*N*-(3-methylpyrid-2-yl)benzofurancarboxamide,
 2-ethyl-7-methoxy-4-*N*-(2-chloropyrid-3-yl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-methoxyphenyl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-chloropyrid-3-yl)benzofurancarboxamide,
 2-acetyl-7-methoxy-4-*N*-(2-chloro-6-methylphenyl)benzofurancarboxamide,
 15 2-(1-hydroxyethyl)-7-methoxy-4-*N*-(3,5-dichloropyrid-4-yl)benzofuran-
 carboxamide,
 2-(3-pyrid-3-yl-1-oxopropyl)-7-methoxy-4-*N*-(3,5-dichloropyrid-4-
 yl)benzofurancarboxamide,
 2-(1-benzyloxyimino)ethyl-7-methoxy-4-*N*-(3,5-dichloropyrid-4-
 20 yl)benzofurancarboxamide,
 2-ethyl-7-methoxy-4-*N*-(3-carboxyphenyl)benzofurancarboxamide,
 2-ethyl-7-methoxy-4-*N*-(4-carboxyphenyl)benzofurancarboxamide, and
 2-[1-(2,2-Dimethylpropyl)]-7-methoxy-4-*N*-(3,5-dichloropyrid-4-
 yl)benzofurancarboxamide.
- 25 10. A compound of any preceding claim, in the form of an enantiomer or mixture
 of enantiomers.
11. A pharmaceutical composition for therapeutic use comprising a compound of
 any preceding claim and a pharmaceutically-acceptable carrier or excipient.
12. Use of a compound of any of claims 1 to 10, for the manufacture of a
 30 medicament for use in the treatment of a disease state capable of being modulated
 by inhibition of phosphodiesterase IV or Tumour Necrosis Factor.

13. The use of claim 12, wherein the disease state is a pathological condition associated with a function of phosphodiesterase IV, eosinophil accumulation or a function of the eosinophil.
14. The use of claim 13, wherein the pathological condition is selected from
5 asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, rheumatoid arthritis, gouty arthritis and other arthritic conditions, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome, diabetes insipidus, keratosis, atopic eczema, atopic dermatitis,
10 cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, depression, cardiac arrest, stroke and intermittent claudication.
15. The use of claim 13, wherein the pathological condition is selected from chronic bronchitis, allergic rhinitis and adult respiratory distress syndrome.
- 15 16. The use of claim 12, wherein the disease state is capable of being modulated by TNF inhibition.
17. The use of claim 16, wherein the disease state is an inflammatory disease or autoimmune disease.
18. The use of claim 17, wherein the disease state is selected from joint
20 inflammation, arthritis, rheumatoid arthritis, rheumatoid spondylitis and osteoarthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, pulmonary sarcoidosis, asthma, bone resorption diseases, reperfusion injury, graft vs host reaction, allograft rejection, malaria,
25 myalgias, HIV, AIDS, ARC, cachexia, Crohn's disease, ulcerative colitis, pyresis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes mellitus, psoriasis, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, inflammatory bowel disease and leukaemia.
19. The use of claim 14 or claim 18, wherein the pathological condition or
30 disease state is asthma.
20. The use of claim 18, wherein the disease state is acute respiratory distress syndrome, pulmonary inflammatory disease or pulmonary sarcoidosis.

21. The use of claim 18, wherein the disease state is joint inflammation.
22. The use of claim 13 or claim 17, wherein the disease state is tardive dyskinesia.
23. The use of claim 16, wherein the disease state is a yeast or fungal infection.
5. 24. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament for use in gastroprotection.
25. Use of a compound of any of claims 1 to 10, for the manufacture of a medicament for use as an analgesic, anti-tussive or anti-hyperalgesic in the treatment of neurogenic inflammatory disease associated with irritation and pain.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/03012

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D307/80 C07D405/12 A61K31/44 A61K31/34 C07D307/79
C07D405/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 187 387 A (KAKEN PHARMA CO LTD) 16 July 1986 cited in the application see abstract; claims 1,26; examples	1-25
P,A	EP 0 685 475 A (BAYER AG) 6 December 1995 see page 2, line 1 - line 13; claims; examples 233,234	1-25

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "&" document member of the same patent family

Date of the actual completion of the international search

4 March 1997

Date of mailing of the international search report

12.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 96/03012

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0187387 A	16-07-86	CA 1260947 A	26-09-89
		DE 3565262 A	03-11-88
		JP 1874807 C	26-09-94
		JP 62155269 A	10-07-87
		US 4666931 A	19-05-87

EP 0685475 A	06-12-95	CA 2150300 A	01-12-95
		JP 7330751 A	19-12-95
